NCT01357681View on ClinicalTrials.gov

Effects of EGCG (Epigallocatechin Gallate) in Huntington's Disease (ETON-Study)

PHASE2CompletedINTERVENTIONAL
Enrollment

54

Participants

Timeline

Start Date

September 30, 2011

Primary Completion Date

May 31, 2015

Study Completion Date

May 31, 2015

Conditions
Huntington Disease
Interventions
DRUG

(2)-epigallocatechin-3-gallate (EGCG)

Month 01:400 mg /day (200-0-200) Month 02:800 mg /day (400-0-400) Month 03 -12: 1200 mg /day (600-0-600)

DRUG

Placebo

Placebo

Trial Locations (3)

10117

Department of Neuropsychiatry, Berlin

44791

Neurologische Klinik der Ruhr-Universität Bochum, Bochum

89081

Universitätsklinikum Ulm, Klinik für Neurologie, Ulm

All Listed Sponsors
lead

Charite University, Berlin, Germany

OTHER

NCT01357681 - Effects of EGCG (Epigallocatechin Gallate) in Huntington's Disease (ETON-Study) | Biotech Hunter | Biotech Hunter